Save information for later
Sign Up

Learn About Ovarian Carcinosarcoma

What is the definition of Ovarian Carcinosarcoma?
Ovarian carcinosarcoma, also known as a malignant mixed mullerian tumor (MMMT) of the ovary, is a rare, aggressive cancer of the ovary with characteristics of two types of cancer: carcinoma and sarcoma. Because women with this cancer often have no symptoms, more than half of women are diagnosed at an advanced stage. When present, symptoms may include pain in the abdomen or pelvic area, bloating or swelling of the abdomen, quickly feeling full when eating, or other digestive problems. The cause of Ovarian carcinosarcoma is not yet understood.
What are the alternative names for Ovarian Carcinosarcoma?
  • Ovarian carcinosarcoma
  • MMMT of the ovary
  • Malignant mixed Müllerian tumor of the ovary
  • Malignant mixed mullerian tumor of the ovary
  • Ovarian malignant mixed Müllerian tumor
  • Ovarian malignant mixed epithelial mesenchymal tumor
Who are the top Ovarian Carcinosarcoma Local Doctors?
Elite in Ovarian Carcinosarcoma
Obstetrics and Gynecology | Oncology
Elite in Ovarian Carcinosarcoma
Obstetrics and Gynecology | Oncology

Yale University

800 Howard Ave, 
New Haven, CT 
Languages Spoken:
English
Offers Telehealth

Alessandro Santin is an Obstetrics and Gynecologist and an Oncologist in New Haven, Connecticut. Dr. Santin is rated as an Elite provider by MediFind in the treatment of Ovarian Carcinosarcoma. His top areas of expertise are Ovarian Carcinosarcoma, Endometrial Cancer, Ovarian Cancer, Hysterectomy, and Salpingo-Oophorectomy.

Elite in Ovarian Carcinosarcoma
Gynecologic Oncology | Oncology
Elite in Ovarian Carcinosarcoma
Gynecologic Oncology | Oncology

Health First Medical Group LLC

1130 Hickory St, 
Melbourne, FL 
Languages Spoken:
English, German, Spanish
Accepting New Patients
Offers Telehealth

Gulden Menderes is a Gynecologic Oncologist and an Oncologist in Melbourne, Florida. Dr. Menderes is rated as an Elite provider by MediFind in the treatment of Ovarian Carcinosarcoma. Her top areas of expertise are Ovarian Carcinosarcoma, Endometrial Cancer, Ovarian Cancer, Lymphadenectomy, and Hysterectomy. Dr. Menderes is currently accepting new patients.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Ovarian Carcinosarcoma
Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Elite in Ovarian Carcinosarcoma
Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Smilow Cancer Center Hospital At Yale New Haven, 20 York Street, 
New Haven, CT 
Languages Spoken:
English

Gloria Huang is a Gynecologic Oncologist and an Oncologist in New Haven, Connecticut. Dr. Huang is rated as an Elite provider by MediFind in the treatment of Ovarian Carcinosarcoma. Her top areas of expertise are Ovarian Carcinosarcoma, Ovarian Cancer, Endometrial Cancer, and Adult Soft Tissue Sarcoma.

What are the latest Ovarian Carcinosarcoma Clinical Trials?
MC1963 Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for Patients With Advanced Stage Ovarian Cancer: A Phase II Double-Blind Randomized Clinical Trial (FAROUT)

Summary: This phase II trial compares the effect of folate receptor alpha dendritic cells (FRαDCs) to placebo in treating patients with stage III or IV ovarian, fallopian tube or primary peritoneal cancer. FRαDCs, a dendritic cell vaccine, is made from a person's white blood cells. The white blood cells are treated in the laboratory to make dendritic cells (a type of immune cell) mixed with folate receptor...

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase 1 Study of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers

Summary: This phase I trial tests the safety, side effects, and best dose of combination therapy with pelcitoclax (APG-1252) and cobimetinib in treating patients with ovarian and endometrial cancers that have come back after a period of improvement (recurrent). APG-1252 is a drug that inhibits activity of proteins that prevent cell death, leading to increased cell death and reduced cell growth. Cobimetinib...

Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center

What are the Latest Advances for Ovarian Carcinosarcoma?